E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pulmonary Arterial Hypertension |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064911 |
E.1.2 | Term | Pulmonary arterial hypertension |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the maximum tolerated dose (MTD) of BPS-MR in pulmonary arterial hypertension (PAH) patients, following chronic, twice daily administration. |
|
E.2.2 | Secondary objectives of the trial |
Safety (adverse events, physical exam, vital signs, tolerability to BPS-MR, clinical laboratory parameters, electrocardiogram findings).
Patients pharmacokinetics parameters at MTD, including estimates of AUC∞, AUC0-12, Cmax, tmax, t1/2, CL/F and Vz/F. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A PAH patient must meet all of the following criteria: 1) Is male or female between the ages of 18 and 75 years of age, inclusive;
2) Has idiopathic or familial PAH, PAH associated with collagen vascular disease, or PAH induced by anorexigens;
3) Is clinically stable, as determined by the Investigator
4) Has previously undergone a cardiac catheterization which is consistent with PAH, specifically PAPm ≥ 25mmHg (at rest), PCWP (or left ventricular end diastolic pressure) ≤ 15mmHg, and PVR > 3 wood units;
5) Has been on a course of an endothelial receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5) or the combination for at least 90 days at the time of the Baseline visit;
6) Has an unencouraged six-minute walk distance (6MWD) between 300 and 600 meters at the screening visit;
7) Is able to communicate effectively with study personnel;
8) Is considered to be reliable, willing, cooperative and compliant with the study protocol requirements;
9) Provides voluntary, written informed consent before participating in the study;
10) Is, if female, physiologically incapable of childbearing or is practicing an acceptable method of birth control (i.e. surgical sterilization, approved hormonal contraceptives, barrier methods [ such as a condom or diaphragm] used with spemicide, or an intrauterine device). |
|
E.4 | Principal exclusion criteria |
Any Patient who meets any of the following criteria will be excluded from the study: 1) Has pulmonary venous hypertension, pulmonary veno-occlusive disease, Pulmonary capillary hemangiomatosis , severe chronic obstructive pulmonary disease, pulmonary hypertension related to congenital heart disease, or chronic thromboembolic pulmonary hypertension;
2) Is pregnant or lactating;
3) Has a known intolerance to beraprost sodium or prostanoids;
4) Has a pre-existing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs;
5) Current use of tobacco products;
6) Known history of syncope
7) Has, in the opinion of the Investigator, any concomitant disease other than those accepted as part of the inclusion criteria that would compromise the patient or the study;
8) Has had a change in or discontinued any PAH medication (with the exception of anticoagulants) within 30 days prior to the Baseline visit;
9) Has received any prostanoid therapy within 30 days prior to the Baseline visit or be scheduled to receive additional prostanoid therapy during the study except for acute vasodilstory testing;
10) Has received any investigational medication within 30 days prior to the Baseline visit or be scheduled to receive another investigational drug during the course of this study;
11) In the opinion of the investigator, may be unable to comply with the study protocol;
12) Has any pre exisiting disease known to cause pulmonary hypertension (e.g. obstructive lung disease, parasitic disease affecting the pulmonary system, sickle cell anemia, mitral valve stenosis, portal hypertension) other than those listed in the inclusion criteria;
13) Has donated blood or plasma or has lost a volume of blood > 450mL within six weeks prior to the Baseline visit. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The objective of this study is to determine the maximun tolerated dose (MTD) of BPS-MR in pulmonary arterial hypertension (PAH) patients, following chronic, twice-daily administration. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Information not present in EudraCT |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |